Kyverna Therapeutics, Inc.
KYTXNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | |
|---|---|---|---|
| Revenue | — | — | — |
| Operating income | −$169.8M | −$142.6M | −$62.4M |
| Net income | −$161.3M | −$127.5M | −$60.4M |
| Total assets | $293.8M | $304.6M | $75.2M |
| Total liabilities | $61.5M | $38.1M | $26.0M |
| Equity | $232.3M | $266.6M | −$13.1M |
| EPS (diluted) | $-3.64 | $-3.33 | $-89.61 |
| Shares out. | 43.2M | 43.2M | 1.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −69.4%
- Return on assets
- −54.9%
- Return on capital (ROCE)
- −66.0%
- Liabilities / assets
- 20.9%
- Debt / equity
- 0.26×
- Book value / share
- $5.37
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 0.87distress
- Accruals / assets
- −2.6%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2026-03KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
- Phase 2Active Not Recruitingreadout ~2026-04KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome
- Phase 1/2Active Not Recruitingreadout ~2026-08KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
- Phase 2Active Not Recruitingreadout ~2027-04KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
- Phase 2/3Recruitingreadout ~2027-09KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Phase 1/2Active Not Recruitingreadout ~2028-10KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Northpond Ventures Iii, LpPassive (13G)Feb 17, 2026
- Bain Capital Life Sciences Opportunities Iii, LpPassive (13G)Feb 17, 2026
- Westlake Biopartners Fund I, L.P.Passive (13G)Feb 6, 2026
- Gordonmd Global Investments LpPassive (13G)Nov 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 5.3M | 6.2 | +2.4% |
| Apr 30, 2026 | 5.2M | 3.0 | +22.0% |
| Apr 15, 2026 | 4.2M | 6.2 | +0.5% |
| Mar 31, 2026 | 4.2M | 6.2 | +0.2% |
| Mar 13, 2026 | 4.2M | 6.3 | +0.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Other material eventMay 18, 2026
- Results of operationsMay 12, 2026
- Other material eventMay 4, 2026
- Regulation FD disclosureApr 22, 2026
- Regulation FD disclosureApr 22, 2026
- Regulation FD disclosureApr 20, 2026
- Results of operationsMar 26, 2026
- Director / officer change · Other material eventFeb 24, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.